Halozyme Therapeutics (HALO) Share-based Compensation Growth (3y) (2013 - 2026)
Halozyme Therapeutics (HALO) Share-based Compensation Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 244.08% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -50.27% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -0.04% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 38.45% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Halozyme Therapeutics | 9.55 Bn | 9.23 Bn | 297.47 Mn | -25.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.19% |
| Dec 31, 2025 | 15.18% |
| Sep 30, 2025 | -34.03% |
| Jun 30, 2025 | -30.00% |
| Mar 31, 2025 | 31.05% |
| Dec 31, 2024 | 40.02% |
| Sep 30, 2024 | 25.59% |
| Jun 30, 2024 | 30.30% |
| Mar 31, 2024 | -53.69% |
| Dec 31, 2023 | -57.07% |
| Sep 30, 2023 | 26.41% |
| Jun 30, 2023 | -55.58% |
| Mar 31, 2023 | -36.54% |
| Dec 31, 2022 | 240.01% |
| Sep 30, 2022 | 26.85% |
| Jun 30, 2022 | -35.00% |
| Mar 31, 2022 | -20.60% |
| Dec 31, 2021 | 16.79% |
| Sep 30, 2021 | 54.12% |
| Jun 30, 2021 | -46.17% |